$SRRK

FLIER JEFFREY S. sold $164K of SRRK

FLIER JEFFREY S. sold 3,053 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.88 ($53.53–$54.88, $0.16M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FLIER JEFFREY S.
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
high confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The disclosed open-market sale by a director, executed under a pre-arranged 10b5-1 plan, is typically not a standalone fundamental driver for the stock.

02

Market read

Traders may note the insider selling signal, but the 10b5-1 structure suggests limited incremental information for valuation.

03

What to watch

The article does not state whether the director’s remaining holdings changed meaningfully versus prior plans, nor does it provide context on total compensation or prior sale cadence.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-06 for a sale executed 2026-07-01.

Background

The article is an SEC Form 4 insider transaction disclosure for Scholar Rock Holding Corp (SRRK).

Company-level read

Ticker impact

$SRRKNeutralHigh confidence
Context

Scholar Rock Holding director Jeffrey S. Flier sold about 3,053 shares in open-market transactions under a 10b5-1 plan, totaling $164,490.

Expected impact

Limited near-term impact; any effect is likely short-lived unless paired with other negative company news.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through from a single director sale under 10b5-1.

None indicated.

None indicated.

Counterpoint

Insider sales can still coincide with private information, but the 10b5-1 designation materially lowers that probability.

Key entities

  • Scholar Rock Holding Corp

    Company whose director insider sale is disclosed via SEC Form 4.

  • FLIER JEFFREY S.

    Director who sold shares in open-market transactions under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BMYHighAI 8/10

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

Bristol Myers Squibb (BMY) awaits an FDA decision on Sept. 30 for expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy. Egetis Therapeutics (EGTX) faces a Sept. 28 decision for Emcitate for MCT8 deficiency. Scholar Rock (SRRK), Biofrontera (BFRI), and Mirum Pharmaceuticals (MIRM) received early FDA approvals for their respective drugs. Mirum's shares rose 3% in pre-market trading.

$BMYHighAI 8/10

FDA Decision Watch: BMY, EGTX Await Key Rulings As BFRI, SRRK, MIRM Win Early Approvals

Bristol Myers Squibb (BMY) and Egetis Therapeutics (EGTX) await FDA decisions on drug expansions. Biofrontera (BFRI), Scholar Rock (SRRK), and Mirum Pharmaceuticals (MIRM) received early approvals. BMY's Camzyos, if approved, would be the first cardiac myosin inhibitor for adolescents with oHCM. EGTX's Emcitate could be the first FDA-approved treatment for MCT8 deficiency. SRRK and BFRI shares declined post-approval, while MIRM shares rose.

$NVOMed

Weight-loss drug developers line up to tap lucrative market

The weight-loss drug market is growing rapidly, with analysts projecting $100B in annual sales in the next decade. Novo Nordisk and Eli Lilly lead the sector, but other companies like Pfizer, Viking Therapeutics, and AstraZeneca are developing new treatments. Key drugs include Novo's amycretin and CagriSema, Pfizer's PF-3944, and Lilly's retatrutide, with varying degrees of success in clinical trials.

$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

$SRRKMedAI 9/10

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

Scholar Rock Holding (SRRK) received FDA approval for ISEMBYLD, a treatment for spinal muscular atrophy in patients aged 2+. The drug showed a 2.2-point advantage over placebo in motor ability tests. The company is launching the product in the U.S., with support programs for insurance and infusions. Commercial success depends on patient access and treatment persistence, with safety concerns and reimbursement terms being key factors.